Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

S2292Reported by Committee

Over-the-Counter Monograph Drug User Fee Amendments

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-07-15
Introduced
3
Cosponsors
S
ⓘ
Type

Sponsor

Jim Banks
Jim Banks
Republican · IN · Senator
Votes with party: 33.5% (319 recorded votes)

Full profile: /officials/B001299

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Tim Kaine (D-VA)Original· 2025-07-15
  • Andy Kim (D-NJ)· 2025-07-29
  • Jon Husted (R-OH)· 2025-07-29

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.

2025-09-08

Source: Congress.gov

Committee Activity

Currently in

  • Senate Committee on Health, Education, Labor, and PensionsReported By · 2025-09-08

Previously

  • Health, Education, Labor, and Pensions CommitteeReported By · 2025-09-08
  • Health, Education, Labor, and Pensions CommitteeMarkup By · 2025-07-30
  • Senate Committee on Health, Education, Labor, and PensionsMarkup By · 2025-07-30
  • Health, Education, Labor, and Pensions CommitteeReferred To · 2025-07-15
  • Senate Committee on Health, Education, Labor, and PensionsReferred To · 2025-07-15

Plain-English Summary

Over-the-Counter Monograph Drug User Fee Amendments This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA); revises procedures used by the Food and Drug Administration (FDA) to evaluate topical, nonprescription drugs (e.g., sunscreens); and requires the FDA to clarify the process through which a prescription drug may be switched to nonprescription status. Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the FDA, rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective. The bill reauthorizes the collection of OMUFA fees from OTC drug facilities through FY2030 and revises methods for calculating such fees. Separately, the bill requires the FDA to allow for the use of real-world evidence to demonstrate the safety and effectiveness of active ingredients in topical, nonprescription drugs. The FDA must consider nonclinical tests and other alternatives to animal testing in evaluating such drugs. The FDA must also issue guidance to clarify the application process for nonprescription drugs, including applications to switch a prescription drug to nonprescription status. The FDA must plan to engage stakeholders in identifying drugs that are promising candidates for a switch. Moreover, applicants seeking a switch may request to meet with the FDA to develop a plan for the requisite application. Finally, the Government Accountability Office must report on (1) the OTC monograph drug supply chain, and (2) the FDA’s handling of applications to switch a prescription drug to nonprescription status.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • S4658A bill to amend title 5, United States Code, to include Parkinson's disease in the list of illnesses and diseases deemed to be proximately caused by employment in fire protection activities, and for other purposes.
    Referred to Committee · 2026-06-02
  • S4607A bill to provide for Department of Defense and Department of Agriculture joint research and development activities, and for other purposes.
    Referred to Committee · 2026-05-20
  • S4525Securing Innovation and Research from Adversaries Act
    Referred to Committee · 2026-05-14
  • S4519Medical Device Electronic Labeling Act
    Referred to Committee · 2026-05-13